Formosa Pharmaceuticals (台新藥) is a late-preclinical and early clinical stage biopharmaceutical company with focus in ophthalmology, oncology, and anti-microbial indications. In August, 2017, Formosa Pharmaceuticals completed the acquisition of Activus Pharma, based in Funabashi, Japan. With the acquisition of the Activus Pure Nanoparticle Technology (APNT) Platform, Formosa Pharmaceuticals enters the ophthalmology disease area with two late-preclinical assets and the goal of expanding the platform’s scope and application. APNT effectively reduces API particle size to improve dissolution and bioavailability without the drawbacks of heavy metal contamination other platforms often experience.